Alloplex Biotherapeutics develops a cellular therapeutic platform for treating cancer.
Alloplex Biotherapeutics has raised $20.0M in total funding. The most recent round was Series A. The last funding was announced in February 2023.
Alloplex Biotherapeutics's investors include Daewoong Pharmaceutical, HanAll Biopharma.
Alloplex Biotherapeutics is headquartered in Boston, United States.
Alloplex Biotherapeutics develops a cellular therapeutic platform for treating cancer.
Alloplex Biotherapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alloplex Biotherapeutics — Funding & Investors." VCBacked, February 14, 2023, https://www.vcbacked.co/company/alloplex-biotherapeutics. Accessed October 29, 2026.
VCBacked. (2023). Alloplex Biotherapeutics — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/alloplex-biotherapeutics
{{cite web |title=Alloplex Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alloplex-biotherapeutics |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated